Status:
NOT_YET_RECRUITING
Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient
Lead Sponsor:
Universitas Padjadjaran
Conditions:
Anogenital Warts
HIV Infection
Eligibility:
All Genders
15-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Warts are a common viral infection of the skin and are prevalent throughout the world, with an overall prevalence in the United States estimated at 2-20%. The incidence of anogenital warts occurs more...
Detailed Description
Research Design Research on the response to administration of intralesional PPD-2TU therapy in warts to changes in levels of various cytokines locally and systemically. Data, Data Collection Techniqu...
Eligibility Criteria
Inclusion
- Anogenital warts whose diagnosis is made based on anamnesis and physical examination, before receiving intralesional purified protein derivative injection therapy.
- All stored biological materials that have been previously taken through tissue from anogenital warts patients whose diagnosis was confirmed based on history and physical examination, 3 weeks after receiving the first intralesional purified protein derivative injection therapy.
Exclusion
- 1\. With a history of allergies to purified protein derivative, generalized dermatitis, asthma and skin allergies 2. Currently taking immunosuppressant or immunomodulatory drugs based on the history and clinical examination.
- 3\. Have an immunodeficiency disease based on anamnesis and clinical examination, except for HIV based on anamnesis, clinical examination and serological examination (anti-HIV).
- 4\. Have a history of suffering from malignancy based on history and clinical examination.
- 5\. Infected with tuberculosis based on history, clinical examination and chest radiography.
- 6\. Infected with other STIs based on history, clinical examination, and serological examination (venereal disease research laboratory (VDRL), Treponema pallidum hemagglutination assay (TPHA), and Hepatitis B surface antigen (HBsAg)).
Key Trial Info
Start Date :
September 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06587542
Start Date
September 15 2024
End Date
December 31 2025
Last Update
September 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.